SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

VSTM Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor

VSTM Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.